Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STARTRK-NG: Entrectinib in Pediatric Solid and CNS Tumors
NCT02650401Phase 2Active, not recruiting
- Sponsor
- Roche
- Start
- May 2016
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 9
01
Overview
A Phase 2 trial of entrectinib in solid tumor, central nervous system tumor, neuroblastoma, sponsored by Roche. Started May 2016; status: active, not recruiting.
02
Drugs
entrectinib
03
Conditions
solid tumorcentral nervous system tumorneuroblastoma
Beyond the preview
Go deeper on NCT02650401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02650401.